Overview
- BioNTech confirmed Monday that it found no buyers for its Tübingen, Marburg and Idar‑Oberstein sites and will close Tübingen at the end of 2027, Marburg in early 2028 and Idar‑Oberstein at the end of 2028, affecting about 1,800 employees.
- The company said sales failed because of low utilization, industry overcapacity and a difficult market for investors, so it will instead wind down operations and negotiate exit terms.
- Management agreed supplementary severance arrangements with the group works council to ease job losses, but the company has not disclosed the size of individual payouts.
- BioNTech reported a €1.35 billion net loss for the first half of 2026 and said shrinking demand for COVID‑19 boosters and high restructuring costs are driving its shift toward oncology and immunotherapies.
- Founders Uğur Şahin and Özlem Türeci will leave by year‑end to start a new firm called Arife while remaining shareholders, and the company completed a selective disposal by selling JPT Peptide to the Dubag Group.